Those who are currently looking into stocks that have recorded significant gains this year so far could have a look at the Seelos Therapeutics Inc (NASDAQ: SEEL) stock. The stock has been one of the major gainers this year so far and has managed to clock gains of as big as 300%.
The rally in the stock continued on Wednesday as it jumped by another 18% following a buy recommendation from an analyst. Bert Hazlett, who is an analyst at BTIG, gave the buy rating and also set the target price of the Seelos stock at $14 a share.
The recommendation from Hazlett came about after Seelos made an announcement about its new device partnership with Aptar Pharma. As per the provisions of this new partnership, the company will be able to use the Biodose Liquid System from Aptar in SLS 002, its intranasal ketamine product. Considering the performance of the Seelos stock and the latest developments, it might be a good idea for investors to include the stock in their watch lists.
CEO and Editor in Chief.
Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life